APONTIS PHARMA Shareholders Invited to Tender Shares with Premium Offer

Zentiva AG has announced a voluntary public purchase offer for APONTIS PHARMA shares, available to shareholders starting today until 21 November 2024. The offer price is set at EUR 10.00 per share, representing a 52.9% premium over the closing share price on 15 October 2024. This offer is notably higher than the average premiums in similar German transactions over the past three years.

The Management Board and Supervisory Board of APONTIS PHARMA support this offer, recommending shareholders accept it, pending a review of the offer document. Zentiva aims to acquire 100% of APONTIS PHARMA's share capital, valuing the company at EUR 85 million.

Zentiva's main shareholder, Paragon, has agreed to sell its 37.5% stake at EUR 9.00 per share. The completion of this transaction requires meeting a minimum acceptance threshold of 65% and regulatory approvals, expected by early 2025.